Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
26 hedge funds and large institutions have $40.3M invested in Trillium Therapeutics Inc. in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
4% less capital invested
Capital invested by funds: $42.1M → $40.3M (-$1.73M)
10% less funds holding
Funds holding: 29 → 26 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
75% less call options, than puts
Call options by funds: $3K | Put options by funds: $12K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$405K |
| 2 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
+$123K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$113K |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$13K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$413K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$209K |
| 3 |
Renaissance Technologies
New York
|
-$157K |
| 4 |
Millennium Management
New York
|
-$82K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$36.6K |
TRIL Hedge Fund Activity: Q3 2018 in Review
26 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2018, worth a combined $40.3M — down 4.1% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRIL and 2 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $405K. The largest seller was Cormorant Asset Management, cutting an estimated $413K.
- 26 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2018, down from 29 in Q2 2018.
- Funds reported $40.3M of Trillium Therapeutics Inc. stock for Q3 2018, down 4.1% quarter-over-quarter.
- 2 funds opened new Trillium Therapeutics Inc. positions in Q3 2018 and 5 closed out, a net change of -3 holders.
- The largest Trillium Therapeutics Inc. buyer in Q3 2018 was Morgan Stanley, an estimated $405K added.
- The largest Trillium Therapeutics Inc. seller in Q3 2018 was Cormorant Asset Management, an estimated $413K sold.
Based on aggregated 13F filings for Q3 2018.